Caplin Point Laboratories Ltd logo

Caplin Point Laboratories Ltd

CAPLIPOINT NSE

Key Fundamentals

SmallcapPharmaceuticalsHealthcare
Market Cap
₹19,280 Cr
Volatility
Moderate
P/E Ratio
29.01
EBITDA
₹761 Cr
Return on Equity
18.75%
Debt to Equity
0
Book Value
₹471.83
EPS
₹62.84
52W High
₹2,699
52W Low
₹1,500.3

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Caplin Point Laboratories Ltd insights

53 extracted metrics + investor summaries across FY13–FY26.

Log in — free

Tapetide Score

Data-driven rating, 0–100. How it works →

Technical Indicators

Key Insights

Strengths

4
  • Company has reduced debt.
  • Company is almost debt free.
  • Company has delivered good profit growth of 21.9% CAGR over last 5 years
  • Company's median sales growth is 19.9% of last 10 years

Growth Rate

Revenue Growth
7.54% ↗
Net Income Growth
21.33% ↗
Cash Flow Change
35.80% ↗
ROE
-4.63% ↘
ROCE
-2.26% ↘
EBITDA Margin (Avg.)
-9.60% ↘

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 5d ago
AI opinion · based on fundamentals
Risk medium

Caplin Point Laboratories is an ₹18,851 Cr market cap specialty pharma company that achieved consolidated revenue of ₹2,034 Cr in FY25 (up 15.5% YoY) and PAT of ₹541 Cr (up 17.3% YoY). The company trades at a PE of 27.8x with a 10-year profit CAGR of 30% and is virtually debt-free, while deriving roughly 85% of revenue from Latin America and Francophone Africa with a growing US injectable business.

Bull Case 8
  • Virtually debt-free balance sheet with debt-to-equity near zero, providing financial flexibility and low interest burden
  • Consistent profit compounding at 30% CAGR over 10 years and 22% CAGR over 5 years demonstrates durable earnings growth
  • FY25 consolidated revenue grew 15.5% YoY to ₹2,034 Cr with PAT up 17.3% YoY to ₹541 Cr, maintaining double-digit growth trajectory
  • Return on equity has remained consistently high at 21-25% over the past decade (3-year average 22%, 5-year average 23%), indicating efficient capital allocation
  • US subsidiary revenue tripled YoY in Q1 FY27, with 18 ANDA approvals (out of 20 filed) and a focus on complex sterile injectables and ophthalmics addressing a $473 Mn+ market opportunity
  • EBITDA margin of 38.4% in Q1 FY27 and gross margin of 59.8% significantly exceed Indian pharma peer averages of ~15-20% EBITDA margins
  • Stock CAGR of 27% over 10 years and 35% over 3 years reflects sustained value creation and market re-rating
  • Median sales growth of 19.9% over the last 10 years with compounded sales CAGR of 16% over 5 years shows revenue consistency across cycles
Bear Case 8
  • Approximately 85% of revenue is concentrated in Latin America and Francophone Africa, exposing the company to currency, political, and regulatory risks in emerging markets
  • PE of 27.8x is at a premium to many mid-cap pharma peers, leaving limited room for execution misses without de-rating
  • Dividend yield of just 0.16% suggests minimal cash return to shareholders despite strong profitability
  • US business (Caplin Steriles) is still scaling with only 18 ANDA approvals versus large generic players with 200+ approvals, facing intense pricing pressure in the US generics market
  • 52-week high/low data unavailable, but 3-year stock CAGR of 35% implies valuation has run ahead of the 20% profit CAGR over the same period, suggesting stretched expectations
  • Latin American markets often involve a stock-and-sell distribution model with credit risk, and currency devaluations in countries like Argentina and Nigeria can compress reported margins
  • TTM sales growth of 15% and profit growth of 18% represent a deceleration from the 10-year CAGR of 25% sales and 30% profit growth, indicating a maturing growth trajectory
  • Price-to-book of 5.25x implies the market is pricing in significant future growth; any slowdown in the US ramp-up or Latin America demand could trigger a correction

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 16h ago
Positives 1
  • Q1FY27 PAT up 18.8% YoY Aug 12

    Net profit rose 18.8% YoY to ₹179 crore for Q1FY27, driven by strong US and Latin America sales. Board recommended a final dividend of ₹4 per share.

Neutral 3
  • New WTD, MD re-appointed Aug 12

    D. Muralidharan appointed as Whole-Time Director and Dr. Sridhar Ganesan re-appointed as Managing Director for two-year terms effective August 2026.

  • AGM record date set Sep 18 Aug 12

    September 18, 2026 fixed as record date for 35th AGM and potential final dividend for FY26.

  • Q1 FY27 earnings call held Jul 30

    Conference call scheduled and held on August 12, 2026 at 4:30 PM IST to discuss June 2026 quarter results under SEBI Regulation 30.

TL;DR: Caplin Point delivered a solid Q1FY27 with 18.8% profit growth and announced a ₹4/share dividend, signalling confidence in cash flows. No visible headwinds emerged this period. Leadership continuity with the MD re-appointment adds stability. The trend is positive with strong earnings momentum, though sustaining US and LatAm growth will be key to watch in coming quarters.

Quarterly Results

  Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
395
410
436
453
459
483
493
502
510
534
543
600
610
Expenses
269
273
293
308
307
318
331
334
332
345
353
396
397
Operating Profit
127
137
142
145
152
165
162
168
178
189
190
204
213
OPM %
32%
34%
33%
32%
33%
34%
33%
33%
35%
35%
35%
34%
35%
Other Income
12
21
17
17
19
21
31
26
23
30
34
28
34
Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
Depreciation
11
12
14
16
16
17
16
17
16
18
19
19
22
PBT
127
146
145
146
154
168
177
177
184
201
204
213
225
Tax %
18%
20%
18%
17%
19%
22%
21%
18%
18%
20%
19%
19%
20%
Net Profit
104
116
120
121
125
131
140
145
151
160
166
173
179
EPS in Rs
13.62
15.13
15.43
16.01
16.31
17.21
18.28
18.76
20.1
20.32
21.56
22.38
23.27
Figures in ₹ Crores

Profit & Loss

  Jun 2015Mar 2016 9mMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
252
239
402
540
649
863
1,061
1,269
1,467
1,694
1,937
2,187
2,287
Expenses
192
175
276
345
417
603
732
874
1,025
1,142
1,287
1,426
1,491
Operating Profit
60
64
125
195
232
260
329
395
442
552
651
761
797
OPM %
24%
27%
31%
36%
36%
30%
31%
31%
30%
33%
34%
35%
35%
Other Income
3
4
10
13
19
41
23
38
55
66
92
116
126
Interest
1
0
1
1
1
0
2
1
1
1
1
1
1
Depreciation
8
7
13
19
23
32
37
47
45
53
66
73
78
PBT
53
60
121
188
227
269
314
386
451
564
677
803
844
Tax %
23%
24%
21%
23%
22%
20%
20%
20%
16%
18%
20%
19%
—
Net Profit
41
46
96
145
177
215
251
308
377
461
541
650
678
EPS in Rs
5.43
6.05
12.65
19.15
23.35
28.42
32.03
39.56
49.57
60.19
70.56
84.36
87.53
Div. Payout %
18%
20%
12%
10%
9%
9%
9%
10%
9%
8%
8%
5%
—
Figures in ₹ Crores

Balance Sheet

  Jun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
15
15
15
15
15
15
15
15
15
15
15
15
Reserves
78
113
210
349
582
858
954
1,252
1,649
2,084
2,619
3,571
Borrowings
2
2
1
1
36
113
235
219
222
219
222
5
Other Liabilities
134
137
133
136
109
139
159
250
305
380
352
454
Total Liabilities
229
267
358
500
743
1,126
1,364
1,736
2,191
2,698
3,208
4,045
Fixed Assets
113
144
152
169
227
272
305
287
280
453
546
605
CWIP
31
0
3
15
10
20
14
18
221
117
144
209
Investments
0
0
17
47
70
61
11
89
281
376
590
859
Other Assets
85
122
186
269
436
772
1,033
1,343
1,410
1,753
1,928
2,373
Total Assets
229
267
358
500
743
1,126
1,364
1,736
2,191
2,698
3,208
4,045
Figures in ₹ Crores

Cash Flow

  Jun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
50
42
68
66
83
45
269
337
271
318
432
523
Investing
-23
-6
-36
-69
-100
-54
-30
-377
-216
-319
-333
-582
Financing
-9
-14
-7
-12
90
80
-24
-41
-28
-38
-38
-46
Net Cash Flow
19
23
25
-14
73
70
215
-81
27
-39
61
-106
Free Cash Flow
24
34
43
18
18
-32
195
246
78
173
241
275
CFO/OP
103
92
73
53
54
38
102
106
81
77
86
88
Figures in ₹ Crores

Ratios

  Jun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
8
12
30
85
90
97
96
91
98
117
119
138
Inventory Days
37
57
44
44
47
210
139
149
159
183
159
181
Days Payable
112
168
155
144
76
57
68
102
84
116
103
125
Cash Conversion Cycle
-67
-99
-81
-16
61
251
166
138
173
184
175
194
Working Capital Days
-128
-114
-29
47
104
167
145
165
144
166
174
263
ROCE %
68%
62%
68%
63%
45%
33%
28%
28%
26%
26%
26%
25%

Shareholding Pattern

As of Jun 2026
Promoters 70.57%
Public 14.62%
Others 6.56%
FIIs 5.75%
DIIs 2.49%
Total 99.99%
  Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters
69.03%
69.03%
69.03%
68.91%
68.89%
68.88%
68.88%
68.80%
70.66%
70.63%
70.63%
70.62%
70.62%
70.56%
70.56%
70.56%
70.56%
70.56%
70.57%
70.57%
70.57%
70.57%
FIIs
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
3.09%
2.85%
3.34%
3.37%
3.70%
4.86%
5.73%
6.17%
6.51%
6.59%
6.15%
5.75%
DIIs
1.28%
1.44%
1.14%
1.16%
1.20%
1.07%
1.12%
1.12%
0.65%
0.26%
0.20%
0.43%
1.09%
1.49%
1.84%
2.11%
2.01%
2.22%
2.10%
2.05%
2.14%
2.49%
Government
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Public
22.94%
21.69%
20.93%
20.79%
20.79%
20.76%
19.00%
18.91%
18.73%
18.57%
18.31%
18.36%
17.59%
17.50%
17.12%
15.77%
15.11%
14.32%
14.20%
14.13%
14.46%
14.62%
Others
6.75%
7.85%
8.90%
9.13%
9.12%
9.28%
11.00%
11.17%
9.96%
10.53%
7.77%
7.74%
7.36%
7.08%
6.78%
6.70%
6.59%
6.73%
6.61%
6.65%
6.68%
6.56%
No. of Shareholders
68,076
69,524
83,462
85,577
83,829
84,868
84,538
82,687
82,146
78,956
78,068
79,438
81,409
80,411
96,123
92,702
96,387
94,169
93,753
93,705
93,896
94,385

Documents

Frequently Asked Questions about Caplin Point Laboratories Ltd

What does Caplin Point Laboratories Ltd do?
Caplin Point Laboratories Ltd is engaged in the manufacturing and sourcing of APIs, finished formulations, R&D, clinical research with presence in Latin America, Africa, USA and other nations.[1]
Where is Caplin Point Laboratories Ltd (CAPLIPOINT) listed?
Caplin Point Laboratories Ltd is listed on the Indian stock exchanges. It is listed on NSE: CAPLIPOINT and BSE: 524742. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Caplin Point Laboratories Ltd belong to?
Caplin Point Laboratories Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Caplin Point Laboratories Ltd?
Caplin Point Laboratories Ltd has a market capitalisation of approximately ₹19279.61 Cr. Based on this, it is classified as a Mid Cap stock.
What is the PE ratio of Caplin Point Laboratories Ltd?
The Price-to-Earnings (PE) ratio of Caplin Point Laboratories Ltd is 29.01. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Caplin Point Laboratories Ltd?
Over the past 52 weeks, Caplin Point Laboratories Ltd has traded between a low of ₹1,500.3 and a high of ₹2,699. This range helps investors understand the stock's price volatility and recent trading levels.
Does Caplin Point Laboratories Ltd pay dividends?
Yes, Caplin Point Laboratories Ltd has a dividend yield of 0.32%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Caplin Point Laboratories Ltd?
Caplin Point Laboratories Ltd has a Return on Equity (ROE) of 18.75%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Caplin Point Laboratories Ltd on Tapetide?
On Tapetide, you can view Caplin Point Laboratories Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

Caplin Point Laboratories Ltd is engaged in the manufacturing and sourcing of APIs, finished formulations, R&D, clinical research with presence in Latin America, Africa, USA and other nations.[1]

Website caplinpoint.net
CEO Dr. Sridhar Ganesan
Employees 3,966
Listed 1994-11-16
Face Value ₹ 2
Issued Size 7,60,11,696

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List